title: Influence of one-year treatment with lovastatin on myocardial remodeling and ischemia in patients with coronary artery disease.
abstract: OBJECTIVE
  Emerging evidence assumes that statins have a benefit to influence the myocardial remodeling and ischemia in patients with coronary artery disease (CAD). Our aim was to investigate the possible and direct favorable effects of lovastatin on left ventricular (LV) systolic, diastolic function and myocardial ischemia in patients with CAD.
  
  
  METHODS
  This randomized prospective study consisted of 83 patients (46 males; mean age 54.3 ± 6.5 years) with CAD and dyslipidemia. All patients were randomized to following groups: the 1st group (n=44) received lovastatin (20-60 mg/day), hypolipidemic diet and physical training; the 2nd group (n=39) - hypolipidemic diet and physical training. Lipid spectrum, Doppler-echocardiography, bicycle exercise test and 24-hour ambulatory electrocardiographic monitoring were done at baseline and were repeated after 12 months of treatment. The data were analyzed by using the paired and unpaired Student's t-tests.
  
  
  RESULTS
  In the 1st group there was an improvement of lipid spectrum (p=0.05) without significant changes of liver transaminases and other side effects. After treatment LV ejection fraction increased from 59.8 ± 8.04 to 62.9 ± 4.43% in lovastatin alone group (p=0.01). Unlike 2nd group, the 1st group's patients had also reduction of myocardial ischemia: increased exercise time (5.21 ± 1.81 vs. 5.96 ± 1.76 min; p=0.05), METS (4.42 ± 0.6 vs. 4.78 ± 0.7; p=0.05), magnitude (1.12 ± 0.34 vs. 0.81 ± 0.19 mm; p=0.05) and duration (2.16 ± 0.67 vs. 1.04 ± 0.46 min, p=0.01) of ST segment depression , as well as number of leads with ST segment depression (2.18 ± 0.72 vs. 1.31 ± 0.67; p=0.05).
  
  
  CONCLUSIONS
  Lipid-lowering therapy with lovastatin improved the LV systolic function and decreased myocardial ischemia.
authors.affiliation: Department of Faculty Therapy, Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan. alinakg@gmail.com
authors.forename: Alina
authors.initials: A
authors.lastname: Kerimkulova
authors.forename: Aygul
authors.initials: A
authors.lastname: Noruzbaeva
authors.forename: Olga
authors.initials: O
authors.lastname: Lunegova
authors.forename: Irina
authors.initials: I
authors.lastname: Gotfrid
authors.forename: Aybek
authors.initials: A
authors.lastname: Mirrakhimov
authors.forename: Nailya
authors.initials: N
authors.lastname: Davydova
authors.forename: Cholpon
authors.initials: C
authors.lastname: Moldokeeva
authors.forename: Erkin
authors.initials: E
authors.lastname: Mirrakhimov
mesh_terms: D000328:Adult; D000368:Aged; D003324:Coronary Artery Disease / Q000150:complications / Q000188:drug therapy*; D018752:Diet, Fat-Restricted; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy*; D004452:Echocardiography; D015716:Electrocardiography, Ambulatory; D015444:Exercise; D005080:Exercise Test; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008148:Lovastatin / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000517:prevention & control; D011446:Prospective Studies; D013318:Stroke Volume; D016277:Ventricular Function, Left / Q000187:drug effects; D020257:Ventricular Remodeling / Q000187:drug effects*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D008148:Lovastatin